Gregory B Lesinski PhD

Gregory B Lesinski PhD
Asst ProfessorCollege of
302B Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
  • Molecular Carcinogenesis and Chemoprevention

General Research Interest

Immunotherapy, Experimental Therapeutics, Melanoma, Immunomodulatory effects of natural products.

Research Description

Dr. Lesinski’s research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Of particular interest are inhibition of the oncogenic STAT3 pathway and maximizing the effect of immune based therapy.

Transinstitutional Work

Dr. Lesinski is collaborating with numerous members of the OSU CCC in conducting correlative laboratory studies for human clinical trials involving immune-based therapies.  He is a long-time collaborator with his former mentor, Dr. William E. Carson, III investigating the role of microRNA in melanoma and how immune stimulating cytokines elicit anti-tumor activity.  Dr. Lesinski is a member of the multidisciplinary Molecular Targeted Therapy (MTT) group, led by Dr. Pui Kai-Li, who are developing novel small molecule inhibitors of pro-oncogenic pathways in tumor cells.  Finally, Dr. Lesinski is working in collaboration with Dr. Steve Clinton to examine how natural products with chemopreventative activity modulate immune function.

Current Publications

  • Olencki TA phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.J Immunother 37 180-6 4/1/2014
  • Friedman AA mathematical model for pancreatic cancer growth and treatments.J Theor Biol 351C 74-82 3/1/2014
  • Carson WE 3rdA Phase I Trial of Bortezomib and Interferon-a-2b in Metastatic Melanoma.J Immunother 37 55-62 1/1/2014
  • Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston MHypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells.J Surg Res 184(2) 855-60 10/1/2013
  • Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GBPRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27(Kip1.).PLoS One 8(9) e74710 9/30/2013
  • Lesinski GBThe potential for targeting the STAT3 pathway as a novel therapy for melanoma.Future Oncol 9(7) 925-7 7/1/2013
  • Mace TA, Bloomston M, Lesinski GBPancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment.Oncoimmunology 2(7) e24891 7/1/2013
  • Mace TA, Ameen Z, Collins A, Wojcik SE, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GBPancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.Cancer Res 73(10) 3007-18 5/15/2013
  • Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CMHeat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.Blood 121(2) 351-9 1/10/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: